RAMIPRIL-2.5 CAPSULE

Država: Kanada

Jezik: angleščina

Source: Health Canada

Kupite ga zdaj

Prenos Lastnosti izdelka (SPC)
27-01-2016

Aktivna sestavina:

RAMIPRIL

Dostopno od:

SIVEM PHARMACEUTICALS ULC

Koda artikla:

C09AA05

INN (mednarodno ime):

RAMIPRIL

Odmerek:

2.5MG

Farmacevtska oblika:

CAPSULE

Sestava:

RAMIPRIL 2.5MG

Pot uporabe:

ORAL

Enote v paketu:

100/500

Tip zastaranja:

Prescription

Terapevtsko območje:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Povzetek izdelek:

Active ingredient group (AIG) number: 0122858004; AHFS:

Status dovoljenje:

CANCELLED POST MARKET

Datum dovoljenje:

2016-06-29

Lastnosti izdelka

                                1
PRODUCT MONOGRAPH
PR
RAMIPRIL-2.5
PR
RAMIPRIL-5
PR
RAMIPRIL-10
RAMIPRIL CAPSULES, MANUFACTURER’S STANDARD
2.5 MG, 5.0 MG AND 10.0 MG
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
SIVEM PHARMACEUTICALS ULC
4705 DOBRIN STREET
SAINT-LAURENT, QUEBEC
DATE OF PREPARATION:
H4R 2P7
JANUARY 12, 2016
CONTROL NO.: 190207
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
.......................................................................................................
10
DRUG INTERACTIONS
.......................................................................................................
15
DOSAGE AND ADMINISTRATION
...................................................................................
17
OVERDOSAGE
......................................................................................................................
23
ACTION AND CLINICAL
PHARMACOLOGY..................................................................
18
STORAGE AND STABILITY
...............................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 26
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
...............................................................................
23
CLINICAL TRIALS
.........................................................................................................
                                
                                Preberite celoten dokument
                                
                            

Dokumenti v drugih jezikih

Lastnosti izdelka Lastnosti izdelka francoščina 27-01-2016

Opozorila o iskanju, povezana s tem izdelkom